Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Iroko Names David U’Prichard to Company’s Board

Abstract:
Iroko Pharmaceuticals LLC, a privately-held specialty pharmaceutical company, announced today that David C. U'Prichard, Ph.D., has joined the Company's Board.

Iroko Names David U’Prichard to Company’s Board

Philadelphia, PA | Posted on November 17th, 2010

Dr. U'Prichard brings to Iroko nearly 30 years of executive experience in every segment of the life-sciences industry, including global pharmaceutical corporations, public and private biotechnology companies and venture-capital firms, in addition to extensive board experience with biotechnology and specialty pharmaceutical companies

Dr. U'Prichard is President of industry consultants Druid Consulting LLC and a Venture Partner at the investment firm Red Abbey LLC. His senior roles in biotechnology have included his tenure as Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc., which he led through rapid expansion, an initial public offering and eventual acquisition by Johnson & Johnson.

Earlier, Dr. U'Prichard served as President and Chairman, R&D, SmithKline Beecham Pharmaceuticals (a corporate predecessor of GlaxoSmithKline), and Executive Vice President and International Research Director, Zeneca Pharmaceuticals (a corporate predecessor of AstraZeneca), among other positions. He has served on numerous corporate and editorial boards and authored 73 scientific papers published in primary, peer-reviewed journals.

"We welcome Dr. U'Prichard to our Board as Iroko takes the next step in its strategy for growth," said Osagie Imasogie, Board Chairman at Iroko and Senior Managing Partner of Phoenix IP Ventures (PIPV), an investor in Iroko.

"With the most recent round of private investment in Iroko, we intend to accelerate clinical development of our nanoparticle formulations of NSAIDs for the treatment of acute and chronic pain while continuing to build our current business in marketing prescription pharmaceuticals. Dr. U'Prichard brings to these efforts his extensive experience in developing medicines to address clear medical needs and in guiding young companies to build their commercial value."

Dr. U'Prichard commented, "Iroko is advancing a clinical pipeline to produce new treatment options for pain management, a therapeutic area with which I have extensive technical and business experience. I look forward to working with the Company to deliver on the promise of this important work."

Last month Iroko announced new funding from an investment vehicle advised by Kew Capital LLP and Phoenix IP Ventures-III which enables Iroko to drive the development of its near-term pipeline formulated with the nanotechnology of its partner iCeutica Inc. Iroko has completed two Phase II clinical programs and is progressing a third Phase II study. Iroko markets the branded products Aldomet® (methyldopa) and Indocin® (indomethacin) internationally and Vancocin® (vancomycin hydrochloride) in Canada.

####

About Iroko Pharmaceuticals
Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops and maximizes the potential of currently marketed pharmaceutical products. Iroko increases the revenues of acquired products through focused selling and marketing efforts and product-life-cycle management activities including development of relevant formulations to improve patient treatment. Iroko currently has three products under development, formulated by iCeutica's proprietary SoluMatrix™ Platform technology.

About Kew Capital LLP
Kew Capital is a private investment advisor formed in 2008. Kew advises on a global portfolio of investments including bonds, listed and private equities, funds, listed and OTC derivatives, structured products and real estate.

About Phoenix IP Ventures
A fully integrated Private Equity and Venture Capital Fund which specializes in life sciences, principally in the pharmaceutical sector. The Fund acquires intellectual property protected assets that meet its criteria for value maximization. Phoenix IP Ventures works in collaboration with major players in the financial community to scale its own proprietary investments in transactions identified and managed by the Firm.

For more information, please click here

Contacts:
Iroko Pharmaceuticals, LLC
John Vavricka, +1-267-546-3009
President & Chief Executive Officer

Copyright © Iroko Pharmaceuticals

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Oxford Instruments Asylum Research Introduces the MFP-3D InfinityTM AFM Featuring Powerful New Capabilities and Stunning High Performance April 18th, 2014

Conductive Inks: booming to $2.8 billion by 2024 April 17th, 2014

Investments/IPO's/Splits

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014

Announcements

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Oxford Instruments Asylum Research Introduces the MFP-3D InfinityTM AFM Featuring Powerful New Capabilities and Stunning High Performance April 18th, 2014

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE